David Flockhart

David A. Flockhart (1952–2015) was a Scottish medical researcher who was a leader in the field of personalised medicine.[1] He was especially known for his work on factors affecting the use of tamoxifen to treat breast cancer such as variability in the level of the CYP2D6 enzyme.[2][3]

References
  1. "In death, there is life", The Economist, p. 84, 26 March 2016
  2. "David Flockhart : Obituary", Edinburgh Evening News, 3 December 2015
  3. In Memoriam, David A. Flockhart PhD, MD, Indiana University Department of Medicine, 26 November 2015
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.